INNATE PHARMA (EPA:IPH) Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES

Transparency directive : regulatory news

08/01/2010 18:00

PRESS RELEASE

HALF-YEAR REPORT ON INNATE PHARMA'S LIQUIDITY CONTRACT WITH NATIXIS SECURITIES

Marseilles, France, January 8, 2010

Under the liquidity contract entrusted by Innate Pharma to Natixis Securities,
the following assets appeared on the liquidity account as at December 31,
2009:

   · 69,741 shares of Innate Pharma, and
   · 121,955.05 euros in cash.

For information, the following assets appeared on the liquidity account at its
start:

   · 300,000 euros in cash.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.
The Company has two drug candidates currently in Phase II clinical trials. Two
of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at
December 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code         FR0010331421
Ticker code       IPH

Disclaimer:

This press release contains information on the markets on which the Company
operates and forward-looking statements. Although the Company believes this
information and these expectations are based on reasonable assumptions, this
information and these forward-looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ materially from
those anticipated. For a discussion of risks and uncertainties which could cause
the Company's actual results, financial condition, performance or achievements
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(www.amf-france.org) or on Innate Pharma's website (www.innatepharma.com).

.

For additional information, please contact:

Innate Pharma                   Alize Public Relations
Laure-Hélène Mercier,           Caroline Carmagnol
Director, Investor Relations    Phone: +33 (0)1 42 68 86 40
Phone: +33 (0)4 30 30 30 87     Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.fr      caroline@alizerp.com

100108_Liquidity contract HY report

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories